These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 33804659)
1. Synthesis and Biological Evaluation of 2,3,4-Triaryl-1,2,4-oxadiazol-5-ones as p38 MAPK Inhibitors. Romeo R; Giofrè SV; Chiacchio MA; Veltri L; Celesti C; Iannazzo D Molecules; 2021 Mar; 26(6):. PubMed ID: 33804659 [TBL] [Abstract][Full Text] [Related]
2. Azastilbenes: a cut-off to p38 MAPK inhibitors. Poon JF; Alao JP; Sunnerhagen P; Dinér P Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors. Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Kim DK; Lim JH; Lee JA; Dewang PM Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921 [TBL] [Abstract][Full Text] [Related]
5. A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia. Willemen HL; Campos PM; Lucas E; Morreale A; Gil-Redondo R; Agut J; González FV; Ramos P; Heijnen C; Mayor F; Kavelaars A; Murga C Biochem J; 2014 May; 459(3):427-39. PubMed ID: 24517375 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel Substituted N,N'-Diaryl ureas as Potent p38 Inhibitors. Zhu D; Li X; Zhong W; Zhao D Molecules; 2015 Sep; 20(9):16604-19. PubMed ID: 26378516 [TBL] [Abstract][Full Text] [Related]
7. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. Pinsetta FR; Taft CA; de Paula da Silva CH J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842 [TBL] [Abstract][Full Text] [Related]
8. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors. Kulkarni RG; Laufer S; Mangannavar C; Garlapati A Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566 [TBL] [Abstract][Full Text] [Related]
10. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors. Park H; Lee S; Hong S Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807 [TBL] [Abstract][Full Text] [Related]
11. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy. Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470 [TBL] [Abstract][Full Text] [Related]
12. Identification of benzimidazole containing 4 Lakshmanan K; Byran G J Recept Signal Transduct Res; 2021 Apr; 41(2):153-158. PubMed ID: 32752909 [TBL] [Abstract][Full Text] [Related]
13. Substituted Benzamides from Anti-inflammatory and p38 Kinase Inhibitors to Antitubercular Activity: Design, Synthesis and Screening. Kulkarni R; Mitkari U; Achaiah G; Laufer S; Bikshapti DVRN; Chandrashekar VM; Gurav PB; Joshi SJ; Chipade VD Mini Rev Med Chem; 2018; 18(17):1486-1497. PubMed ID: 28685700 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents. Ma Z; Pan Y; Huang W; Yang Y; Wang Z; Li Q; Zhao Y; Zhang X; Shen Z Bioorg Med Chem Lett; 2014 Jan; 24(1):220-3. PubMed ID: 24332090 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells. Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685 [TBL] [Abstract][Full Text] [Related]
17. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590 [TBL] [Abstract][Full Text] [Related]
18. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors. Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097 [TBL] [Abstract][Full Text] [Related]
19. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach. Badrinarayan P; Sastry GN J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417 [TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]